Home » Somatuline Depot Receives Marketing Approval in the U.S. for the Treatment of Acromegaly
Somatuline Depot Receives Marketing Approval in the U.S. for the Treatment of Acromegaly
Ipsen announced that the FDA has approved for marketing Somatuline Depot (lanreotide) Injection 60, 90 and 120 mg in the U.S.
Ipsen
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May